上海宏成药业有限公司是成都倍特药业的控股子公司,主要从事大分子药物研发和生产,以抗肿瘤,自身免疫类疾病、抗感染为主。建立从抗体发现到IND申报的各个平台,包括抗体、RNA和ADC等多种技术平台。I期实验室总面积2300平米,位于上海原能细胞产业园,已于2020年10月投入使用;临港中试基地建设中;商业化生产基地正在筹备中。
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows